A comparison of the biologic activity of two recombinant IFN-β preparations used in the treatment of relapsing-remitting multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 22, Issue 12, 2002, Pages 1181-1184

  Antonetti, Francesco ^a   Finocchiaro, Ornella ^a   Mascia, Michele ^a   Terlizzese, Maria Grazia ^a   Jaber, Amer ^b,c  

^a Serono International SA   (Switzerland)

^b Laboratoires Serono   (Switzerland)

^c Centre Industriel   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOMBINANT PROTEINS;

EID: 0036975338     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900260475696     Document Type: Article

References (17)

1. CHOFFLON, M. (2000). Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur. J. Neurol. 7, 369-380.
2. GOODIN, D.S. (2001). Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose-response. Drugs 61, 1693-1703.
3. COYLE, P., and HARTUNG, H.P. (2002). Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult. Scler. 8, 2-9.
4. GOODIN, D.S., FROHMAN, E.M., GARMANY, G.P., Jr., HALPER, J., LIKOSKY, W.H., LUBLIN, F.D., SILBERBERG, D.H., STUART, W.H., and VAN DEN NOORT, S. (2002). Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178.
5. PANITCH, H., GOODIN, D.S., FRANCIS, G., CHANG, P., COYLE, P.K., O'CONNOR, P., MONAGHAN, E., LI, D., WEINSHENKER, B., for the EVIDENCE STUDY GROUP and the UNIVERSITY OF BRITISH COLUMBIA MS/MRI RESEARCH GROUP (2002). Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59, 1496-1506.
6. DURELLI, L., VERDUN, E., BARBERO, P., BERGUI, M., VERSINO, E., GHEZZI, A., MONTANARI, E., and ZAFFARONI, M. (2002). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453-1460.
7. ANTONETTI, F., FINOCCHIARO, O., MASCIA, M., TERLIZZESE, M., and JABER, A.A. Comparison of the biological activity of three commercially available β-interferons. Presented at the American Academy of Neurology 53rd Annual Meeting. 2001 [Poster P05.121].
8. PIANI, D., and MALKOWSKI, J.P. (2001). Recombinant interferon-beta 1a (REBIF). J. Biotechnol. 87, 281-283.
9. PETRI, T., and WEBER-DIEHL, F. (1995). Interferon beta-1b for the treatment of multiple sclerosis. J. Biotechnol. 43, 74-75.
10. RUNKEL, L., MEIER, W., PEPINSKY, R.B., KARPUSAS, M., WHITTY, A., KIMBALL, K., BRICKELMAIER, M., MULDOWNEY, C., JONES, W., and GOELZ, S.E. (1998). Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15, 641-649.
11. BURAGLIO, M., TRINCHARD-LUGAN, I., MUNAFO, A., and MACNAMEE, M. (1999). Recombinant human interferon-β-1a (Rebif®) vs recombinant interferon-β-1b (Betaseron®) in healthy volunteers. A pharmacodynamic and tolerability study. Clin. Drug Invest. 18, 27-34.
12. STURZEBECHER, S., MAIBAUER, R., HEUNER, A., BECKMANN, K., and AUFDEMBRINKE, B. (1999). Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J. Interferon Cytokine Res. 19, 1257-1264.
13. DEISENHAMMER, F., MAYRINGER, I., HARVEY, J., DILITZ, E., GASSE, T., STADLBAUER, D., REINDL, M., and BERGER, T. (2000). A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54, 2055-2060.
14. ORRU, S., AMORESANO, A., SICILIANO, R., NAPOLEONI, R., FINOCCHIARO, O., DATOLA, A., DE LUCA, E., SIRNA, A., and PUCCI, P. (2000). Structural analysis of modified forms of recombinant IFN-beta produced under stress-stimulating conditions. Biol. Chem. 381, 7-17.
15. United States Pharmacopoeia, 21st revision. (1985). United States Pharmacopeial Convention, Rockville, MD, pp. 1169-1177.
16. European Pharmacopoeia, 2nd ed. (1993). Part I, VIII 13, Statistical analysis. Sainte-Ruffine, France: Maisonneuve.
17. THE PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON β-1a SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP and the UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. (2001). PRISMS-4: long-term efficacy of interferon β-1a in relapsing MS. Neurology 56, 1628-1636.